| abstract |
The invention relates to the surprising discovery that the biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1R16A, RASSF7, RNF183, SIRT6EM, SIRT6EM, SIRT6EM, SIRT6PJ2, SIRT6P, JIRT SOCS2, and DCN, are expressed differently in control samples compared to samples obtained from patients suffering from endometrial cancer and, therefore, are useful for detecting endometrial cancer. In particular terms, these biomarkers have excellent sensitivity, specificity, and / or ability to separate affected patients from unaffected patients. Moreover, the inventors discovered that the differential expression of these biomarkers in the tumor tissue of primary endometrial cancer correlates with their level of expression in samples obtained from uterine fluid compared to control values. Thus, these biomarkers are consistent in that they can be expressed differently in different types of samples obtained from affected subjects and patients. |